Dashboard
Manage Tickers

GANX Gain Therapeutics, Inc.

Nasdaq gaintherapeutics.com


$ 1.95 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 04:26:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.10 $ 0.00 (0 %)
DIA $ 464.35 $ 0.00 (0 %)
SPY $ 667.38 $ 0.00 (0 %)
TLT $ 90.94 $ 0.00 (0 %)
GLD $ 389.98 $ 0.00 (0 %)
$ 1.87
$ 1.98
$ 1.86 x 200
$ 1.94 x 559
-- - --
$ 1.41 - $ 3.19
1,022,591
na
67.22M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

btig-reiterates-buy-on-gain-therapeutics-maintains-9-price-target
BTIG Reiterates Buy on Gain Therapeutics, ...
10/15/2025 10:04:37

BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.

hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Gain...
10/13/2025 11:15:20

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 pr...

maxim-group-maintains-buy-on-gain-therapeutics-raises-price-target-to-7
Maxim Group Maintains Buy on Gain Therapeu...
10/07/2025 16:09:24

Maxim Group analyst Jason McCarthy maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and raises the price target from $5 ...

gain-therapeutics-presents-phase-1b-gt-02287-data-at-international-congress-of-parkinsons-disease-and-movement-disorders-highlighting-safety-tolerability-and-exploratory-findings-in-pd-patients-with-or-without-gba1-mutation
Gain Therapeutics Presents Phase 1b GT-022...
10/06/2025 12:20:57

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participant...

gain-therapeutics-begins-gt-02287-phase-1b-extension-study-allowing-participants-to-continue-treatment-for-additional-nine-months
Gain Therapeutics Begins GT-02287 Phase 1b...
09/18/2025 11:45:58

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after co...

btig-reiterates-buy-on-gain-therapeutics-maintains-9-price-target
BTIG Reiterates Buy on Gain Therapeutics, ...
09/08/2025 10:07:51

BTIG analyst Thomas Shrader reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 price target.

gain-therapeutics-receives-australian-approval-for-the--phase-1b-dosing-extension-of-gt-022887-study-independent-data-monitoring-committee-recommend-study-continue-with-no-changes-to-design
Gain Therapeutics Receives Australian Appr...
09/04/2025 12:05:50

roth-capital-maintains-buy-on-gain-therapeutics-lowers-price-target-to-6
Roth Capital Maintains Buy on Gain Therape...
08/13/2025 17:14:20

Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target ...

gain-therapeutics-q2-eps-019-misses-017-estimate
Gain Therapeutics Q2 EPS $(0.19) Misses $(...
08/12/2025 11:11:28

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
08/08/2025 21:08:06

gain-therapeutics-announces-pricing-of-public-offering-offering-price-for-each-set-of-two-shares-of-common-stock-and-accompanying-warrant-to-purchase-one-share-of-common-stock-is-311-per-set-of-securities-yielding-effective-price-of-155-per-share-and-001-per-warrant
Gain Therapeutics Announces Pricing Of Pub...
07/16/2025 13:05:02

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/16/2025 12:08:15

us-futures-trade-mixed-as-june-inflation-ticks-up-asml-morgan-stanley-goldman-sachs-bofa-earnings-in-focus
US Futures Trade Mixed As June Inflation T...
07/16/2025 10:08:54

U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchm...

why-data-storage-shares-are-trading-higher-by-35-here-are-20-stocks-moving-premarket
Why Data Storage Shares Are Trading Higher...
07/16/2025 10:04:22

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/15/2025 21:06:55

gain-therapeutics-announces-proposed-public-offering-size-not-disclosed
Gain Therapeutics Announces Proposed Publi...
07/15/2025 20:37:07

hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Gain...
07/03/2025 11:18:49

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 pr...

gain-therapeutics-completes-target-enrollment-in-phase-1b-clinical-study-evaluating-gt-02287-in-people-with-parkinsons-disease-with-or-without-gba1-mutation
Gain Therapeutics Completes Target Enrollm...
06/30/2025 20:10:19

gain-therapeutics-presents-at-2nd-gba1-meeting
Gain Therapeutics Presents At 2nd GBA1 Mee...
05/29/2025 12:45:47

gain-therapeutics-files-for-mixed-shelf-offering-of-100m
Gain Therapeutics Files For Mixed Shelf Of...
05/28/2025 22:05:27

-SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION